Multiple vaccines are now being used across the world, and several studies have described cases of corneal graft rejection following the administration of the COVID-19 vaccine. The purpose of this article is to review the corneal adverse event that occurred following COVID-19 vaccine administration. The literature search was conducted in March 2022 using MEDLINE, PubMed, and the Cochrane Database of Systematic Reviews. A total of 27 articles, including 37 cases, have documented corneal adverse events that occurred following COVID-19 vaccination. The mean age was 60 ± 14.9 years (range, 27–83 years). The most common events were acute corneal graft rejection (n = 21, 56.8%), followed by herpes zoster ophthalmicus (n = 11, 29.7%) and herpes simplex keratitis (n = 2, 5.4%). The mean time from vaccination to the event was 10 ± 8.5 days (range, 1–42 days) after the first or second dose of vaccine. All patients with corneal graft rejection, immune-mediated keratolysis, and peripheral ulcerative keratitis (PUK) (n = 24, 64.9%) were managed topically with or without oral corticosteroids. Patients with herpes zoster ophthalmicus and herpes simplex keratitis were managed with oral antiviral agents. Two patients received penetrating keratoplasty due to keratolysis after invalid topical treatment. Disease resolution was noted in 29 patients (78.3%), whereas 3 (8.1%) had persistent corneal edema after graft rejection, 1 (2.7%) had corneal infiltration after HZO, and 4 (10.8%) were not mentioned in the articles. Corneal adverse events could occur after COVID-19 vaccination. After timely treatment with steroids or antiviral agents, most of the events were mild and had a good visual outcome. Administrating or increasing steroids before vaccination may be useful for the prevention of corneal graft rejection. However, the prophylactic use of antiviral treatments in patients with a herpes viral infection history is not recommend.

To explore the relationship between DED and sleep disorders and examine the impact of DED’s duration on sleep disorders. This multi-institutional, retrospective cohort study used the TriNetX database. We recruited participants with and without DED diagnosis from 2004 to 2023. Dry eye patients were propensity-matched to individuals from our non-DED cohort (1:1 ratio) based on variables such as age (every 5 year), sex, ethnicity, race, and relevant comorbidities. The Cox proportional hazards regression model was utilized to assess the impact of variables on sleep disorder risk, reporting hazard ratios (HRs) with 95% confidence intervals (CI). Kaplan-Meier survival analysis and log-rank tests were applied to estimate the cumulative incidence of sleep disorder. A total of 688,413 DED adult patients (64.91% female; mean age at index 56.96 ± 15.93) and 688,413 propensity-matched non-DED comparators (64.92% female; mean age at index 56.96 ± 15.93) were recruited. Our analysis showed an overall increased risk of uveitis among DED patients at 5-year time points (HR = 1.04) and all-year (19 years) follow-up durations (HR = 1.03). We observed a higher risk of sleep apnea in DED individuals irrespective of follow-up intervals. Further analyses revealed this increased risk specifically in those diagnosed with Sjögren syndrome (HR = 1.22). This study highlights the significant link between sleep disorders and DED, emphasizing the role of sleep apnea in DED patients. Aqueous-deficient DED has a more pronounced impact on sleep disturbances compared to evaporative DED, while the influence of DED on non-physiological insomnia may be overstated.